Drugs / TQ-B3234
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05107037 | Nov 2021 → Dec 2023 | neurofibromatosis type 1 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02996838 | May 2017 → Dec 2020 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07407803 | Mar 2026 → Dec 2027 expected | plexiform neurofibroma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQ-B3234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107037 ↗ |
| Action | Inhibit | “selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor” NCT05107037 ↗ |
| Route | Oral | “TQ-B3234 p.o. qd” NCT02996838 ↗ |